# US 7,611,722 B2 · Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,611,722 B2
- Document ID: US7611722B2
- Status: Granted
- Kind: B2
- Application number: 10/419,536
- Filed: 2003-04-21
- Published: 2003-11-06
- Granted: 2009-11-03
- Earliest claimed: 2001-12-24
- Assignees: Teva Pharmaceutical Industries Ltd.
- Inventors: E. Itzhak Lerner; Vered Rosenberger; Ofer Aqua; Moshe Fleshner-Barak
- Web page: https://patentgrep.com/patent/US7611722B2

## CPC

- A61K 31/663: Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- A61J 3/005: {Coating of tablets or the like (coating of sweetmeats or confectionery A23G3/20; coating of granules in general B01J2/006)}
- A61J 3/10: into the form of compressed tablets (tablet presses B30B11/00)
- A61K 9/2072: {characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms (A61K9/0004, A61K9/0056, A61K9/0065 take precedence)}
- A61K 9/209: {containing drug in at least two layers or in the core and in at least one outer layer}
- A61K 9/2095: {Tabletting processes}
- A61K 31/195: having an amino group
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/433: Thidiazoles
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 19/10: for osteoporosis
- B30B 11/34: for coating articles, e.g. tablets
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61J: CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B30B: PRESSES IN GENERAL (producing ultra-high pressure or ultra-high pressure and high temperature to effect modifications of a substance, e.g. for making artificial diamonds B01J3/00 ){(compressing means for refuse receptacles B65F1/1405)}

## Abstract

A solid dosage form for oral administration to a patient comprising a core tablet sheathed in an annular body of compressed powder or granular material is provided. A preferred embodiment of the solid dosage form reduces contact of the active ingredient in solid form with the mucosa lining the gastrointestinal tract, which is particularly advantageous for delivering an ulcerative drug. A tool set comprising a columnar punch and a punch assembly comprising an annular punch and core rod, and a tableting process for making the solid dosage form are also provided.

## Claims

### Claim 1

A solid pharmaceutical dosage form for oral administration to a patient, comprising:
a recessed core tablet having a substantially exposed first surface and a substantially exposed second surface and an outer surface extending between the exposed first and second opposed surfaces, wherein the first and second substantially exposed surfaces are opposed one to the other, and the substantially exposed surfaces are exposed to the dosage form external environment;
the core tablet containing an active pharmaceutical ingredient; wherein
the core tablet is sheathed in an annular body of compressed powder or compressed granular material that encircles the core tablet, and is in contact with the outer surface of the core tablet, leaving the opposed surfaces of the core tablet substantially exposed;
the annular body having opposed first and second annular faces, an outer surface extending between the annular faces outer edges, and an inner surface extending between the annular faces inner edges, thereby defining an annulus; and wherein
the substantially exposed first and second opposed surfaces of the core tablet are both recessed with respect to the annular faces of the annular body, such that, prior to and following oral administration, the recessed surfaces of the core tablet are shielded from contact with the mucosa lining the gastrointestinal tract.

### Claim 2 (depends on 1)

The solid pharmaceutical dosage form of claim 1, wherein the active pharmaceutical ingredient is released into the annulus of the annular body.

### Claim 3 (depends on 2)

The solid pharmaceutical dosage form of claim 2, wherein the active pharmaceutical ingredient is ulcerative.

### Claim 4 (depends on 3)

The solid pharmaceutical dosage form of claim 3, wherein the active pharmaceutical ingredient is a bisphosphonate or NSAID.

### Claim 5 (depends on 4)

The solid pharmaceutical dosage form of claim 4, wherein the active pharmaceutical ingredient is selected from the group consisting of monosodium alendronate monohydrate, monosodium alendronate trihydrate, sodium etidronate, sodium risedronate, pamidronate, asprin, ibuprofen, naproxen, fenoprofen, ketoprofen, oxaprozin, flubiprofen, indomethacin, sulindac, etodolac, mefenamic acid, meclofenamate sodium, tolmetin, ketorolac, diclofenac, piroxicam, meloxicam, tenoxicam, phenylbutaxone, and oxyphenbutazone.

### Claim 6 (depends on 1)

The solid pharmaceutical dosage form of claim 1, wherein the core tablet comprises sodium alendronate.

### Claim 7 (depends on 5)

The solid pharmaceutical dosage form of claim 5, wherein the active pharmaceutical ingredient is monosodium alendronate monohydrate.

### Claim 8 (depends on 5)

The solid pharmaceutical dosage form of claim 5, wherein the active pharmaceutical ingredient is monosodium alendronate trihydrate.

### Claim 9 (depends on 1)

The solid pharmaceutical dosage form of claim 1, wherein the core tablet is recessed from about 0.5 mm to about 4 mm.

### Claim 10 (depends on 1)

The solid pharmaceutical dosage form of claim 1, wherein the annular body contains an active ingredient.

### Claim 11 (depends on 1)

The solid pharmaceutical dosage form of claim 1, wherein the powder or granular material includes a pharmaceutical excipient selected from the group consisting of hydroxypropyl cellulose, hydroxypropyl methylcelullose, microcrystalline cellulose, starch, lactose, sugars, polyvinylpyrrolidone, and calcium phosphate.

### Claim 12 (depends on 1)

The dosage form of claim 1, wherein the distance across each of the opposed surface of the core tablet is from about 2 mm to about 12 mm.

### Claim 13 (depends on 1)

The dosage form of claim 1, wherein the distance across each of the opposed surfaces of the core tablet is from about 4 mm to about 7 mm.

### Claim 14 (depends on 1)

The dosage form of claim 1, wherein the inner surface of the annular body consists of a first and second terminal segment and one internal segment, further wherein the first terminal segment and the opposed first surface of the core tablet define a first void and the second terminal segment and the opposed second surface of the core tablet define a second void and further wherein the distance across each of the voids is from about 0.5 mm to about 10 mm.

### Claim 15 (depends on 14)

The dosage form of claim 14, wherein the distance across each void is from about 3 mm to about 6 mm.

### Claim 16 (depends on 1)

The dosage form of claim 1 wherein the core tablet is in the shape of a disk or cylinder.

### Claim 17 (depends on 1)

The solid dosage form of claim 1, wherein the first opposed surface of the core tablet is recessed to an extent different from the second opposed surface.

### Claim 18 (depends on 1)

The solid dosage form of claim 1, wherein the cross-section of the core tablet is uniform.

### Claim 19 (depends on 18)

The solid pharmaceutical dosage form of claim 18, wherein the cross-section of the core tablet is cylindrical.

### Claim 20 (depends on 1)

A process for producing a the solid pharmaceutical dosage form of claim 1, comprising forming the annular body of powder or granular material around the core tablet by compression.

### Claim 21 (depends on 20)

The process of claim 20, wherein forming the annular body comprises:
a) filling an annular cavity with the powder or granular material, the annular cavity being defined by:
i) the bore of die,
ii) an annular punch partially inserted into the bore from one side,
iii) a core rod in an extended position wherein it extends through the bore and the annular punch with its tip substantially flush with the surface of the die on the side opposite the annular punch, wherein the core rod is movable between the extended position and a retracted position wherein the tip is inside the bore, and further wherein the core rod is biased in the extended position,
b) placing the core tablet at the tip of the core rod, and
c) advancing a columnar punch toward the bore from the side of the die opposite the annular punch, thereby pushing the core tablet into the bore against the bias force on the core rod and causing the core rod to retract, and compressing the powder or granular material around the core tablet, forming the annular body.

### Claim 22 (depends on 21)

The process of claim 21, wherein the columnar punch contact face has a centered protrusion.

### Claim 23 (depends on 21)

The process of claim 21, further comprising withdrawing at least one of the punches from the die bore after advancing the columnar punch toward the bore and ejecting the solid pharmaceutical dosage form from the bore.

### Claim 24 (depends on 20)

The process of claim 20, wherein the compression step comprises compression on or in a tablet press equipped with the following parts and tooling:
a die table mounting a die with a bore extending therethrough,
a columnar punch mounted on one side of the die table coaxially with the bore and movable along the axis of the bore with the end proximal to the die table sized to be received into the bore and being terminated with a contact face for pressing against the powder or granular material,
an annular punch mounted on the other side of the die table coaxially with the bore and moveable along the axis of the die bore independently of the columnar punch, wherein the end of the annular punch proximal to the die table is sized to be received into the die bore and is terminated with a contact face for pressing against the powder or granular material, and
a core rod slidably engaged within the annulus of the annular punch and aligned coaxially with the die bore, the core rod moveable between a retracted position and an extended position wherein the core rod extends through the die bore with the tip of the rod substantially flush with the surface of the die, the core rod being biased to the extended position by biasing means,
and wherein forming the annular body comprises:
a) filling an annular cavity with the powder or granular material, the annular cavity being defined by the die bore, the core rod in its extended position, and the contact face of the annular punch partially inserted into the bore,
b) placing the core tablet at the tip of the extended core rod,
c) advancing the columnar punch, whereby the core tablet is pushed into the die bore against the bias force exerted by the core rod biasing means, whereby the core rod at least partially retracts, and whereby the powder or granular material is compressed between the contact faces of the columnar and annular punches, forming the annular body.

### Claim 25 (depends on 24)

The process of claim 24, further comprising withdrawing at least one of the punches from the die bore after advancing the columnar punch toward the bore and ejecting the solid pharmaceutical dosage form from the bore.

### Claim 26 (depends on 24)

The process of claim 24, wherein the columnar punch contact face has a centered protrusion.

### Claim 27 (depends on 24)

The process of claim 24, wherein the die table is horizontal, the columnar punch is above the die table, and the annular punch is below the die table, wherein the tablet press is further equipped with a feed shoe for delivering the powder or granular material to the die bore from above and a collar fixedly mounted below the die table coaxially with the die bore, the core rod being slidably engaged within the annulus of the collar and biased by bias means housed in the collar, and wherein, the annular cavity is filled from the feed shoe, the columnar punch is withdrawn after the advancing step and the solid pharmaceutical dosage form is ejected from the bore by advancing the annular punch into the bore.

### Claim 28 (depends on 27)

The process of claim 27, wherein the annular cavity is filled by placing the feed shoe over the die bore while the annular punch is positioned with its contact face approximately flush with the die surface and then lowering the lower punch to form the cavity and drawing the powder or granular material into the cavity by gravity or pressure differential.

### Claim 29 (depends on 20)

The process of claim 20, wherein the compression step comprises compression on or in a tablet press equipped with the following parts and tooling:
a generally planar and circular die table capable of rotation about an axis normal to the plane and having a plurality of bores therethrough around its circumference at regular intervals,
a first punch carrier mounted on one side of the die table and a second punch carrier mounted on the other side of the die table, each punch carrier rotating about the axis synchronously with the die table and provided with a plurality of vertical holes or slots, each hole or slot being in registry with a bore through the die table,
a plurality of annular first punches, each slidably engaged within one of the vertical holes or slots of the first punch carrier, each of the first punches having an end proximal to the die table sized to be received into a bore and being terminated with an annular contact face for pressing against the powder or granular material, each of the first punches further having a core rod slidably engaged within the annulus and aligned coaxially with a die bore, the core rod moveable between a retracted position and an extended position wherein the core rod extends through the die bore with the tip of the rod substantially flush with the surface of the die table, the core rod being biased to the extended position by biasing means,
a plurality of second punches, each slidably engaged within one of the vertical holes or slots of the second punch carrier, each of the second punches having an end proximal to the die table sized to be received into a bore and terminated with a contact face for pressing against the powder or granular material, and
means for controlling the motion of the punches in the direction of the axis,
and wherein forming the annular body comprises:
a) filling an annular cavity with the powder or granular material, the annular cavity being defined by a die bore, a core rod in its extended position and the contact face of a first punch partially inserted into the bore,
b) placing the core tablet at the tip of the extended core rod,
c) advancing a second punch into the die bore, whereby the core tablet is pushed into the die bore against the bias force exerted by the core rod biasing means, whereby the core rod at least partially retracts, and whereby the powder or granular material is compressed between the contact faces of the first and second punch, forming the annular body.

### Claim 30 (depends on 29)

The process of claim 29, further comprising withdrawing at least one of the punches from the die bore after advancing the second punch toward the bore and ejecting the solid pharmaceutical dosage form from the bore.

### Claim 31 (depends on 29)

The process of claim 29, wherein the second punch contact face has a centered protrusion.

### Claim 32 (depends on 29)

The process of claim 29, wherein the annular cavity is filled by rotating the die table under a feed shoe while the first punch is positioned with its contact face substantially flush with the die table surface and then retracting the first punch to form the cavity and drawing the powder or granular material into the cavity by gravity or pressure differential.